Disclosures: Carlos Alventosa-Mateu: Nothing to Disclose, Mara Dolores Ocete Mochn: Nothing to Disclose, Juan Catal Bauset: Nothing to Disclose, Javier Hernndez Felices: Nothing to Disclose, Juan Jos Urquijo Ponce: Nothing to Disclose, Mercedes Latorre Snchez: Nothing to Disclose, Inmaculada Castell Miralles: Nothing to Disclose, Concepcin Cardona Gimeno: Nothing to Disclose, Moiss Diago: Nothing to Disclose 564 ASSOCIATIONS BETWEEN BIOMARKERS AND MAGNETIC RESONANCE IMAGING-DERIVED ANALI SCORE IN PATIENTS WITH PRIMARY SCLEROSING CHOLANGITIS: ANALYSIS FROM THE PHASE 3 PRIMIS STUDY Michael Trauner 1 Jun Xu 2 Xiangyu Liu 3 Kaiyi Zhu 3 Xiaomin Lu 3 Sharlene Lim 3 William Barchuk 3 Lisa Boyette 3 Clare Tempany 4 Zachary Goodman 5 Atsushi Tanaka 6 Douglas Thorburn 7 Cynthia Levy 8 Christopher Bowlus 9 , 1 Medical University of Vienna, 2 Gilead Sciences, Inc., 3 Gilead Sciences Inc., 4 Brigham and Women's Hospital, Harvard University, 5 INOVA Fairfax Hospital, 6 Teikyo University School of Medicine, 7 Royal Free Hospital, 8 University of Miami, 9 University of California, Davis Background and Aim: Magnetic resonance cholangiopancreatography (MRCP) is the standard diagnostic method for patients with primary sclerosing cholangitis (PSC)
It has been concluded that the GPx1 Pro198Leu polymorphism may increase cancer risk by disrupting the equilibrium of antioxidants
Footnotes Source of support : Nil Conflict of interest : None REFERENCES 1.Chalasani N, Younossi Z, Lavine JE, Diehl AM, Brunt EM, Cusi K, Charlton M, Sanyal AJ
Circulating Markers of Oxidative Stress and Polycystic Ovary Syndrome (PCOS): A Systematic Review and Meta-Analysis
This study is an example of BPC-157's action in the presence of only one drug from the NSAID group, but its effect with other drugs from this group consistently shows the same beneficial and desired effect
injections of saline at the same volumetric dose as the active ingredient formulation, following the same dosing schedule as the treatment group
